Nkarta, Inc. NKTX
1.53 USD +0.01 (+0.66%)
At closeNov 3, 2026, 4:26 PM EST
1.53 0.00 0.00%
After hours · Nov 3, 4:26 PM ET
1.52 Day range 1.60
1.48 52-week range 3.72
- YTD
- -17.30%
- 1 year
- -26.09%
News
benzinga.com HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12 HC Wainwright & Co. analyst Douglas Tsao assumes Nkarta (NASDAQ:NKTX) with a Buy rating and announces Price Target of $12.
defenseworld.net Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance Nkarta (NASDAQ: NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including…
marketbeat.com Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance Nkarta NASDAQ: NKTX said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including…
defenseworld.net Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why Nkarta, Inc. (NASDAQ: NKTX - Get Free Report)'s stock price fell 3.5% during trading on Friday. The stock traded as low as $2.73 and last traded at $2.75. 681,083 shares were traded during trading,…
globenewswire.com Nkarta to Participate in September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to…
globenewswire.com Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…
defenseworld.net 6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc. BlackRock Inc. bought a new stake in Nkarta, Inc. (NASDAQ: NKTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,300,212…
benzinga.com Stifel Maintains Buy on Nkarta, Lowers Price Target to $10 Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $11 to $10.
benzinga.com HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14 HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $16 to $14.
benzinga.com Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 74.19 percent decrease over losses of $(0.31)…
globenewswire.com Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1…
globenewswire.com Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.
prnewswire.com The $13 Million Company Teaching the Immune System to Hunt Cancer /PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
benzinga.com Nkarta Q1 EPS $(0.37), Inline Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period…
globenewswire.com Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based…
zacks.com NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
globenewswire.com Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…
globenewswire.com Nkarta to Participate in Needham Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to…
defenseworld.net Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Hold” by Analysts Nkarta, Inc. (NASDAQ: NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has…
benzinga.com Mizuho Maintains Outperform on Nkarta, Lowers Price Target to $12 Mizuho analyst Salim Syed maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price target from $14 to $12.
benzinga.com Nkarta Q4 EPS $(0.37) Misses $(0.34) Estimate Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.34) by 9.79 percent. This is a 5.71 percent decrease over losses of $(0.35) per…
globenewswire.com Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…
defenseworld.net Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two…
globenewswire.com Nkarta to Participate in March Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
defenseworld.net Nkarta, Inc. $NKTX Shares Sold by AWM Investment Company Inc. AWM Investment Company Inc. trimmed its position in shares of Nkarta, Inc. (NASDAQ: NKTX) by 30.0% during the second quarter, according to the company in its most recent Form 13F filing with the…
globenewswire.com Nkarta to Participate in Evercore Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to…
seekingalpha.com Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune diseases, despite current market pessimism. NKX019, the lead CAR-NK candidate, shows promising early…- benzinga.com Stifel Maintains Buy on Nkarta, Lowers Price Target to $11 Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $12 to $11.
- benzinga.com Nkarta Q3 EPS $(0.29) Beats $(0.35) Estimate Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 16.43 percent. This is a 25.64 percent increase over losses of $(0.39) per…
- benzinga.com Nkarta To Present NKX019 Data At ACR Convergence 2025 Showing Immune Reset In Non-Hodgkin Lymphoma And Preclinical Efficacy In Vitro Autoimmune Disease Models Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
- benzinga.com Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- benzinga.com Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D…
benzinga.com Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
- benzinga.com Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 112 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 283 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 109 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 43 companies set new 52-week lows.
- benzinga.com Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.